{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T19:09:03Z","timestamp":1774379343570,"version":"3.50.1"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T00:00:00Z","timestamp":1653264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1007\/s12020-022-03080-1","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T15:03:05Z","timestamp":1653318185000},"page":"349-356","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Resistant prolactinomas: a case series of 26 patients"],"prefix":"10.1007","volume":"77","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2660-9311","authenticated-orcid":false,"given":"Tamar","family":"Eshkoli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9039-5565","authenticated-orcid":false,"given":"Merav","family":"Fraenkel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Zaid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4033-9968","authenticated-orcid":false,"given":"Dayana","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3805-3565","authenticated-orcid":false,"given":"Uri","family":"Yoel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2033-7300","authenticated-orcid":false,"given":"Gloria","family":"Tsvetov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Gorshtein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1682-6435","authenticated-orcid":false,"given":"Adi","family":"Goldbart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4923-488X","authenticated-orcid":false,"given":"Yona","family":"Greenman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9188-3894","authenticated-orcid":false,"given":"Ilan","family":"Shimon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,23]]},"reference":[{"key":"3080_CR1","first-page":"316","volume":"41","author":"A Tirosh","year":"2016","unstructured":"A. Tirosh, I. Shimon, Current approach to treatments for prolactinomas. Minerva Endocrinol. 41, 316\u2013323 (2016)","journal-title":"Minerva Endocrinol."},{"key":"3080_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/nrendo.2011.37","volume":"7","author":"A Colao","year":"2011","unstructured":"A. Colao, S. Savastano, Medical treatment of prolactinomas. Nat. Rev. Endocrinol. 7, 267\u2013278 (2011)","journal-title":"Nat. Rev. Endocrinol."},{"key":"3080_CR3","doi-asserted-by":"publisher","first-page":"101290","DOI":"10.1016\/j.beem.2019.101290","volume":"33","author":"P Chanson","year":"2019","unstructured":"P. Chanson, D. Maiter, The epidemiology, diagnosis and treatment of Prolactinomas: the old and the new. Best. Pract. Res. Clin. Endocrinol. Metab. 33, 101290 (2019)","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"key":"3080_CR4","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1111\/j.1365-2265.2006.02562.x","volume":"65","author":"FF Casanueva","year":"2016","unstructured":"F.F. Casanueva, M.E. Molitch, J.A. Schlechte, R. Abs, V. Bonert, M.D. Bronstein et al. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin. Endocrinol. (Oxf.) 65, 265\u2013273 (2016)","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"3080_CR5","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1210\/jc.2010-1692","volume":"96","author":"S Melmed","year":"2011","unstructured":"S. Melmed, F.F. Casanueva, A.R. Hoffman, D.L. Kleinberg, V.M. Montori, J.A. Schlechte et al. Endocrine Society. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 96, 273\u2013288 (2011)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3080_CR6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1007\/BF03347092","volume":"34","author":"V Vasilev","year":"2011","unstructured":"V. Vasilev, A.F. Daly, L. Vroonen, S. Zacharieva, A. Beckers, Resistant prolactinomas. J. Endocrinol. Invest 34, 312\u2013316 (2011)","journal-title":"J. Endocrinol. Invest"},{"key":"3080_CR7","first-page":"2247","volume":"85","author":"A Colao","year":"2000","unstructured":"A. Colao, A. Di Sarno, M.L. Landi, F. Scavuzzo, P. Cappabianca, R. Pivonello et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in I patients than in patients pretreated with other dopamine agonists: A prospective study in 110 patients. J. Clin. Endocrinol. Metab. 85, 2247\u20132252 (2000)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3080_CR8","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJM199410063311403","volume":"331","author":"J Webster","year":"1994","unstructured":"J. Webster, G. Piscitelli, A. Polli, C.I. Ferrari, I. Ismail, M.F. Scanlon, A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. N. Engl. J. Med. 331, 904\u2013909 (1994)","journal-title":"N. Engl. J. Med."},{"key":"3080_CR9","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1210\/jcem.84.7.5810","volume":"84","author":"J Verhelst","year":"1999","unstructured":"J. Verhelst, R. Abs, D. Maiter, A. van den Bruel, M. Vandeweghe, B. Velkeniers et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J. Clin. Endocrinol. Metab. 84, 2518\u20132522 (1999)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3080_CR10","doi-asserted-by":"publisher","first-page":"4721","DOI":"10.1210\/jc.2007-2758","volume":"93","author":"M Ono","year":"2008","unstructured":"M. Ono, N. Miki, T. Kawamata, R. Makino, K. Amano, T. Seki et al. Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J. Clin. Endocrinol. Metab. 93, 4721\u20134727 (2008)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3080_CR11","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s11060-013-1270-8","volume":"117","author":"ME Molitch","year":"2014","unstructured":"M.E. Molitch, Management of medically refractory prolactinoma. J. Neurooncol 117, 421\u2013428 (2014)","journal-title":"J. Neurooncol"},{"key":"3080_CR12","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1530\/EJE-12-0236","volume":"167","author":"L Vroonen","year":"2012","unstructured":"L. Vroonen, M.L. Jaffrain-Rea, P. Petrossians, G. Tamagno, P. Chanson, L. Vilar et al. Prolactinomas resistant to standard doses of cabergoline: a multicenter study of 92 patients. Eur. J. Endocrinol. 167, 651\u2013662 (2012)","journal-title":"Eur. J. Endocrinol."},{"key":"3080_CR13","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000495775","volume":"109","author":"D Maiter","year":"2019","unstructured":"D. Maiter, Management of dopamine agonist-resistant prolactinoma. Neuroendocrinology 109, 42\u201350 (2019)","journal-title":"Neuroendocrinology"},{"key":"3080_CR14","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1210\/jcem-69-3-500","volume":"69","author":"I Pellegrini","year":"1989","unstructured":"I. Pellegrini, R. Rasolonjanahary, G. Gunz, P. Bertrand, S. Delivet, C.P. Jedynak et al. Resistance to bromocriptine in prolactinomas. J. Clin. Endocrinol. Metab. 69, 500\u2013509 (1989)","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3080_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1159\/000156116","volume":"89","author":"VQ Passos","year":"2009","unstructured":"V.Q. Passos, M.A. Fortes, D. Giannella-Neto, M.D. Bronstein, Genes differentially expressed in prolactinomas responsive and resistant to dopamine agonists. Neuroendocrinology 89, 163\u2013170 (2009)","journal-title":"Neuroendocrinology"},{"key":"3080_CR16","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.3171\/2010.11.JNS101369","volume":"114","author":"MC Oh","year":"2011","unstructured":"M.C. Oh, M.K. Aghi, Dopamine agonist\u2013resistant prolactinomas. J. Neurosurg. 114, 1369\u20131379 (2011)","journal-title":"J. Neurosurg."},{"key":"3080_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1055\/a-1525-2131","volume":"53","author":"R Sari","year":"2021","unstructured":"R. Sari, M.A. Altinoz, E.B.K. Ozlu, A. Sav, A.E. Danyeli, O. Baskan, O. Er, I. Elmaci, Treatment strategies for dopamine agonist-resistant and aggressive prolactinomas: a comprehensive analysis of the literature. Horm. Metab. Res 53, 413\u2013424 (2021)","journal-title":"Horm. Metab. Res"},{"key":"3080_CR18","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.7150\/jca.52937","volume":"12","author":"F Jian","year":"2021","unstructured":"F. Jian, Y. Sun, Q. Sun, B. Zhang, L. Bian, NEK2 regulates cellular proliferation and cabergoline sensitivity in pituitary adenomas. J. Cancer 12, 2083\u20132091 (2021)","journal-title":"J. Cancer"},{"issue":"4","key":"3080_CR19","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/cen.14541","volume":"95","author":"Y Rudman","year":"2021","unstructured":"Y. Rudman, H. Duskin-Bitan, Y. Manisterski, B. Pertzov, A. Akirov, H. Masri-Iraqi, I. Shimon, Long-term response to cabergoline and multi-modal treatment in men with macroprolactinoma: Does size really matter? Clin. Endocrinol. (Oxf.) 95(4), 606\u2013617 (2021)","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"3080_CR20","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s11102-016-0723-4","volume":"9","author":"I Shimon","year":"2016","unstructured":"I. Shimon, E. Sosa, V. Mendoza, Y. Greenman, A. Tirosh, E. Espinosa et al. Giant prolactinomas larger than 60mm in size: a cohort of massive and aggressive prolactin-secreting pituitary adenomas. Pituitary 9, 429\u2013436 (2016)","journal-title":"Pituitary"},{"key":"3080_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-019-01009-y","volume":"23","author":"H Duskin-Bitan","year":"2020","unstructured":"H. Duskin-Bitan, I. Shimon, Prolactinomas in males: any differences? Pituitary 23, 52\u201357 (2020)","journal-title":"Pituitary"},{"key":"3080_CR22","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s11102-021-01188-7","volume":"24","author":"KJ Yagnik","year":"2021","unstructured":"K.J. Yagnik, D. Erickson, I. Bancos, J.L.D. Atkinson, G. Choby, M. Peris-Celda, Van, J.J. Gompel, Surgical outcomes of medically failed prolactinomas: a systematic review and meta-analysis. Pituitary 24, 978\u2013988 (2021)","journal-title":"Pituitary"},{"key":"3080_CR23","first-page":"106","volume":"23","author":"CE Stiles","year":"2021","unstructured":"C.E. Stiles, G. Lloyd, S. Bhattacharyya, R.P. Steeds, K. Boomla, J.P. Bestwick et al. Incidence of cabergoline associated valvulopathy in primary care patients with prolactinoma using hard cardiac endpoints. J. Clin. Endocrinol. Metab. 23, 106 (2021)","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"3080_CR24","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1530\/EJE-11-1000","volume":"166","author":"V Primeau","year":"2012","unstructured":"V. Primeau, C. Raftopoulos, D. Maiter, Outcomes of transsphenoidal surgery in prolactinomas: improvement of hormonal control in dopamine agonist-resistant patients. Eur. J. Endocrinol. May 166(5), 779\u201386 (2012)","journal-title":"Eur. J. Endocrinol. May"},{"key":"3080_CR25","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/cen.12242","volume":"79","author":"AB Moraes","year":"2013","unstructured":"A.B. Moraes, C.M. Silva, L. Vieira Neto, M.R. Gadelha, Giant prolactinomas: the therapeutic approach. Clin. Endocrinol. (Oxf.) 79, 447\u2013456 (2013)","journal-title":"Clin. Endocrinol. (Oxf.)"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03080-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-022-03080-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-022-03080-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T14:35:06Z","timestamp":1659105306000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-022-03080-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,23]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["3080"],"URL":"https:\/\/doi.org\/10.1007\/s12020-022-03080-1","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,23]]},"assertion":[{"value":"24 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The local IRB of each institution approved the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}